key: cord-0787477-azzu3zga authors: Nagamine, Takahiko title: Neuroleptic malignant syndrome associated with COVID-19 vaccination date: 2021-12-17 journal: CJEM DOI: 10.1007/s43678-021-00254-0 sha: d801f11df2bfea33748c8b21b035d91c820d6cce doc_id: 787477 cord_uid: azzu3zga nan Neuroleptic malignant syndrome is a fulminant and lifethreatening disorder that occurs in patients treated with antipsychotic medication. Although the pathophysiology of neuroleptic malignant syndrome is not fully understood, it involves a central hypodopaminergic state and an acute phase reaction as an immune response [1] . We report a case of this syndrome after COVID-19 vaccination. Written consent was obtained from the patient. A 61-year-old Japanese woman was brought to the emergency room with high fever and disorientation. She had developed schizophrenia 35 years ago and had recently been treated with risperidone 6 mg/day. The day before admission, she received an intramuscular injection of 0.3 mL of Comirnaty Ⓡ , a mRNA vaccine against SARS-CoV-2. However, 20 h after the vaccination, she was unable to walk due to muscle pains all over her body and called an ambulance. On arrival, she was confused with a high fever of 40 ℃, tremors in her upper limbs, and muscle stiffness all over her body. She was sweating, had tachycardia of 134/ min and elevated blood pressure of 168/102 mmHg. A quick blood test in the emergency room revealed a creatine kinase > 5000 IU/L, and complete blood count was remarkable for an elevated white blood cell > 10,000/mm 3 . COVID-19 antigen test was negative. Chest X-ray, urine analysis, and blood culture showed no abnormalities. Her symptoms and blood tests clearly met the diagnostic criteria for neuroleptic malignant syndrome [2] . Risperidone was discontinued, and she was admitted to the high care unit for systemic management with massive infusion of fluids. Lead-pipe rigidity improved one week after admission. On the 10th day of hospitalization, her creatine kinase level decreased to 2932 IU/L and she was able to walk. COVID-19 infection increases the risk of developing neuroleptic malignant syndrome [3] , but there are few reports of neuroleptic malignant syndrome associated with COVID-19 vaccination [4] . SARS-CoV-2 binds to the angiotensinconverting enzyme 2 (ACE2) receptors and enters the body. There are many ACE2 receptors in the brain, and it has been speculated that the mechanism by which COVID-19 infection causes neuroleptic malignant syndrome may be via ACE2 receptors [5] . Although the mRNA vaccine promotes the synthesis of viral spike proteins, they do not activate ACE2 receptors, and thus vaccine-induced neuroleptic malignant syndrome is a different mechanism than neuroleptic malignant syndrome caused by COVID-19 infection. After vaccination, immune-transducing cells called dendritic cells begin to work, and synthesizing proinflammatory cytokines [6] . Elevated levels of proinflammatory interleukins such as IL-6 and TNF-α have been reported in neuroleptic malignant syndrome [7] . Thus, the immunostimulatory effect of the vaccine may cause the pathogenesis of neuroleptic malignant syndrome. Funding No funding was provided. Neuroleptic malignant syndrome: a neuroimmunologic hypothesis Neuroleptic malignant syndrome Neuroleptic malignant syndrome in a COVID-19 patient Neuroleptic malignant syndrome following COVID-19 vaccination Comprehensive review on neuro-COVID-19 pathophysiology and clinical consequences Immune memory: an evolutionary perspective Serum cytokine level and production of reactive oxygen species (ROS) by blood neutrophils from a schizophrenic patient with hypersensitivity to neuroleptics